Low-Dose Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Case Report
Minh Dung Nguyen, Gilles Natchagande, Olena Gorobets, Vincent Vinh-Hung
TL;DR
This case report explores the use of a low dose of apalutamide in an elderly patient with prostate cancer, showing a three-year survival without metastasis.
Contribution
The novelty lies in suggesting low-dose apalutamide as a potential treatment option for elderly patients with nonmetastatic prostate cancer.
Findings
A patient survived three years without metastasis on 25% of the recommended apalutamide dose.
Treatment discontinuation during lockdowns did not lead to disease progression.
The case suggests low-dose apalutamide may be effective in elderly patients.
Abstract
The effect of low-dose apalutamide in nonmetastatic castration-resistant prostate cancer is unknown. We report the observation of therapy being administered at 25% of the recommended dose in an 80-year-old patient. Despite treatment discontinuation during COVID lockdowns, he survived three years without evidence of metastasis. This case gently invites us to reflect on the possibility of low-dose apalutamide in the elderly.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProstate Cancer Treatment and Research · Cancer, Lipids, and Metabolism · Multiple Myeloma Research and Treatments